文献速递外周动脉疾病

自体静脉同种异体移植物治疗下肢严重肢体缺血评价:REVATEC(BioproTEC静脉移植物血运重建)研究

Evaluation of Autologous Venous Allograft for Lower Limb in the Treatment of Critical Limb Ischemia. The REVATEC (REVAscularisation Par Greffons Veineux BioproTEC) Study.
PubMed 文献 · Ann Vasc Surg · 2025-01-23

前瞻性多中心队列纳入39例患者(40条肢体),评估Bioprotec®供应冷藏静脉同种异体移植物血运重建后1年保肢率。6个月、1年、2年免于大截肢率分别为79%、75%、68%,一期通畅率6个月77%、1年及2年47%。既往血运重建次数是移植物通畅的显著危险因素(HR 1.59)。

要点

  • 冷藏静脉同种异体移植物1年保肢率75%,2年68%,结果令人鼓舞但通畅率一般。
  • 一期通畅率6个月77%,1年及2年均为47%;二期通畅率6个月82%,1年及2年均为50%。
  • 既往血运重建次数是移植物通畅的显著危险因素(HR 1.59,95%CI 1.13-2.24)。

核心结论

  • 对既往干预失败、再次血运重建极具挑战的严重肢体缺血患者,使用冷藏静脉同种异体移植物显示出令人鼓舞的保肢率,尽管通畅率一般,在某些选择病例中可能代表其他替代物的替代选择。
  • 需要更多研究来确定冷藏静脉同种异体移植物在严重肢体缺血患者中的潜力。

研究设计与样本

  • 前瞻性多中心队列研究,2018年至2021年共纳入39例患者(40条肢体)。
  • 主要终点为冷藏静脉同种异体移植物血运重建后1年保肢率,随访基于临床检查和双功超声。

主要发现

  • 术后30天内无死亡,记录到4例大截肢。
  • 6个月、1年、2年免于大截肢率分别为79%(95%CI 68-93)、75%(95%CI 62-91)、68%(95%CI 51-90)。
  • 6个月、1年、2年生存率分别为95%(95%CI 88-100)、83%(95%CI 71-98)、79%(95%CI 65-96)。
  • 一期通畅率6个月77%(95%CI 64-91),1年及2年均为47%(95%CI 32-70);二期通畅率6个月82%(95%CI 70-95),1年及2年均为50%(95%CI 34-73)。
  • 既往血运重建次数是移植物通畅的显著危险因素(HR 1.59,95%CI 1.13-2.24)。

临床怎么用

  • 作者认为,对既往干预失败的严重肢体缺血患者,冷藏静脉同种异体移植物在某些选择病例中可能作为其他替代物的替代选择。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Critical limb threatening ischemia (CLTI) requires revascularization whenever it is possible. The great saphenous vein represents the surgical conduit of choice. However, it is not always available, in particular in multi-operated patients. In such cases, alternative efficient biological conduits are needed but data remains limited. This study aims at evaluating the performance of cold stored venous allografts provided by Bioprotec® society. METHODS: Prospective multi-center cohort. The primary endpoint was limb salvage rate at 1 year following revascularization with cold stored venous allografts. Follow-up based on clinical examination and duplex-scan. Uni- and multivariate analyses were performed to analyze predictive factors of endpoints. RESULTS: Overall, 39 patients (40 limbs) were included between 2018 and 2021. Patients had a median of 2 [0-6] revascularizations prior to inclusion. A total of 97 grafts were used (median of 3 [1-4] grafts per procedure). In the postoperative period (30 days) no death and 4 major amputations were noted. The median length of follow-up was 13.4 [0.7-31.1] months. The 6-months, 1-year and 2-year freedom from major amputation rates were 79% [95% CI: 68-93], 75% (95% CI 62%-91%) and 68% [95% CI: 51-90], respectively. The 6 months, 1-year and 2-year survival rates were 95% [88-100], 83% [95% CI: 71-98] and 79% [95% CI: 65-96], respectively. Primary patency rates were 77% [95% CI: 64-91] at 6 months, and 47% [95% CI: 32-70] at one and 2 years. Secondary patency rates were 82% [95% CI: 70-95] at 6 months and 50% [95% CI: 34-73] at one and 2 years. The analysis identified the number of previous revascularizations as a significant risk factor for graft patency (Hazard Ratio: 1.59; 95% Confidence Interval: 1.13-2.24). CONCLUSION: Revascularization of CLTI patients with previous failed interventions is highly challenging. The use of cold stored venous allograft showed encouraging limb salvage rate despite modest patency rates and thus may represent an alternative to other substitute in some selected cases. More studies are necessary to identify the potential of CSVA in CLTI patients.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Mercier L, Javerliat I, Jayet J, et al. Evaluation of Autologous Venous Allograft for Lower Limb in the Treatment of Critical Limb Ischemia. The REVATEC (REVAscularisation Par Greffons Veineux BioproTEC) Study. Ann Vasc Surg. 2025. PMID: 39863278. doi:10.1016/j.avsg.2025.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。